Islamic Finance Principles Assessment
Riba — Does Eli Lilly (Ondo Tokenized Stock) involve interest?
LLYON itself is not structured as a debt or interest-bearing instrument; it is a 1:1 token claim on Eli Lilly shares, with value moving in line with the stock and dividends reinvested rather than paid as interest. The main riba exposure is indirect, arising from third-party DeFi platforms (e.g., Euler) that allow borrowing stablecoins against LLYON as collateral, and from Ondo Global Markets' stated plans for future margin/Prime Brokerage integration. For Muslim investors, the token's own design avoids interest, but participation in surrounding lending markets should be avoided.
Assessment: Minor Riba
Score: 75.1/100
Our methodology examines 10 criteria to evaluate how well Eli Lilly (Ondo Tokenized Stock) avoids interest-based mechanisms.
Ondo Global Markets earns revenue through management, minting, and redemption-type fees on tokenized assets, not through interest income tied specifically to LLYON. The underlying Eli Lilly shares are held with a regulated custodian via a US broker-dealer, and the token's total-return structure reinvests dividends (net of withholding tax) into token value rather than distributing them as cash yield. No sources indicate the LLYON product itself holds interest-bearing treasury instruments; its backing is equity, not debt, which is a favorable structural feature from a riba standpoint.
LLYON's core mechanism — mint against deposited fiat/stablecoin used to purchase real shares, redeem during trading hours — contains no lending or borrowing at the protocol level. However, Ondo Global Markets has publicly stated intent to integrate institutional-grade borrowing options directly into its platform, and third-party protocols already permit borrowing against LLYON as collateral via Chainlink oracle feeds. Per the judgment principle, this external or planned lending activity does not itself convert LLYON into an interest-based instrument, but investors should be aware such integrations exist and avoid the interest-bearing legs of them.
Gharar — How much uncertainty does Eli Lilly (Ondo Tokenized Stock) involve?
Uncertainty around LLYON is relatively low for a crypto asset, given its regulated issuance and transparent 1:1 backing, though some structural and disclosure gaps remain. Named leadership, published prospectus terms, and multiple audits reduce ambiguity, while unresolved fee disclosure and a noted centralization risk add mild uncertainty. Overall, this is a comparatively low-gharar instrument for the sector.
Assessment: Minor Gharar (Mostly Clear)
Score: 75.5/100
Our methodology examines 15 criteria including team transparency, audit quality, and governance.
Ondo Finance is led by a named, credentialed CEO with a Goldman Sachs digital-assets background and Brown/Stanford GSB education, supported by a visible team including named operational staff. The firm underwent a two-year SEC investigation into its tokenization activities, which closed without charges — a meaningful transparency and legitimacy signal. LLYON is issued pursuant to a public prospectus for qualified purchasers, with mechanics (broker-dealer purchase, custodial holding, 1:1 minting/redemption) clearly documented, unlike many anonymous or vaguely-described token projects in the space.
The broader Ondo ecosystem has been reviewed by multiple named audit firms, including CertiK (2021), PeckShield (2021), Halborn (2024, 2025), EtherAuthority (2024), and Zellic (2025, covering Global Markets on Solana), indicating sustained third-party scrutiny. Halborn's review flagged centralization risk tied to trusted entities and roles, a disclosed rather than hidden concern. LLYON-specific fee levels are not separately itemized within the broader Ondo Global Markets fee disclosures, which is a minor transparency gap, but overall documentation and audit coverage are stronger than most tokenized products.
Maysir — Does Eli Lilly (Ondo Tokenized Stock) involve gambling or speculation?
LLYON is not designed as a speculative or gambling-style instrument; it is a redeemable, asset-backed tracker of a real, dividend-paying equity. Some gharar-adjacent speculation is possible in secondary-market trading, especially since token trading is continuous while redemption is restricted to trading hours, but this mirrors ordinary equity-derivative mechanics rather than a wagering design. The overall verdict is that LLYON's core structure is productive and utility-driven, not maysir-oriented.
Assessment: Minor Maysir (Incidental)
Score: 79.3/100
Our methodology examines 11 criteria to determine whether Eli Lilly (Ondo Tokenized Stock) is a gambling instrument or a genuine economic tool.
LLYON provides genuine real-world utility: it gives on-chain holders economic exposure to actual Eli Lilly shares, backed 1:1 by holdings at a regulated custodian and purchased through a licensed US broker-dealer. This is a productive use case — capital allocation to a real, revenue-generating pharmaceutical company — rather than a zero-sum bet on token price alone. Institutional adoption across MetaMask, Binance, BNB Chain, and Solana, alongside over $1B TVL and $18B cumulative volume for the Ondo Stocks platform, further evidences use as a functional investment vehicle rather than a speculative novelty.
Weighed against this utility is the reality that tokenized stocks trade continuously on secondary markets even though underlying share redemption only occurs during trading hours, which can invite short-term speculative trading detached from the pace of the real asset. Additionally, unrelated phishing-style impersonation schemes referencing similarly-named tokenized-stock claims have appeared externally, though this is third-party misuse rather than a feature of LLYON itself and does not affect its own ruling. On balance, the token's asset-backed, redeemable design and institutional-grade issuance process outweigh the secondary-market speculative behavior it may attract.
The Full 27-Point Screening
1. Legitimacy (4 criteria)
| Criterion | Score | Analysis |
|---|
| Team Transparency | 90/100 | The issuing firm's founder/CEO and several senior staff are named, credentialed, and publicly traceable via LinkedIn and press coverage. |
| Fraud & Scam Risk | 72/100 | A two-year SEC probe closed without charges is a strong trust signal, though the broader tokenized-stock space shows third-party impersonation/phishing patterns unrelated to Ondo's own conduct. |
| Use Case Legitimacy | 92/100 | LLYON provides clear real-world utility as a 1:1-backed on-chain claim on actual Eli Lilly shares, usable for exposure, trading, and DeFi collateral. |
| Ethical Practices | 62/100 | Pharmaceuticals are not a prohibited sector, but the sources give no data on Eli Lilly's own debt/interest ratios needed for full company-level Shariah screening. |
Summary: The issuer behind LLYON has a named, credentialed founding team and recently cleared a two-year SEC investigation without charges, indicating a genuine, accountable project rather than an anonymous or fraudulent one.
2. Project Operations (9 criteria)
| Criterion | Score | Analysis |
|---|
| Core Protocol Business | 85/100 | The base protocol tokenizes real, custodied equities via a regulated broker-dealer, a business activity in a non-prohibited sector. |
| Transaction Fees | 65/100 | Fees described are management/mint/redemption type rather than interest extraction, but LLYON-specific fee figures are not disclosed. |
| Treasury Assets | 82/100 | LLYON is backed by actual Eli Lilly shares held with a regulated custodian rather than interest-bearing treasury instruments. |
| Revenue Model | 72/100 | Revenue for the tokenized-stock line is fee-based rather than lending-interest-based, though granular LLYON-level figures are not given. |
| Transparency | 68/100 | Documentation, prospectus disclosure requirements, and multiple published audit reports exist for the platform. |
| Governance | 30/100 | The tokenization process is centralized around a broker-dealer, custodian, and trusted operational roles, and an audit explicitly flagged centralization risk. |
| Launch Fairness | 78/100 | There is no traditional pre-mine or ICO for LLYON; tokens are minted on demand at NAV against real purchased shares, though this fair-issuance framing is inferred rather than explicitly stated. |
| Token Distribution | 75/100 | LLYON supply is created/destroyed per real underlying share purchases rather than allocated to insiders, but no explicit distribution data for LLYON itself is provided. |
| Speculation/Utility Ratio | 85/100 | Usage described (institutional adoption, DeFi collateral, large trading volumes) is utility-driven exposure to a real stock rather than hype-driven speculation. |
Summary: LLYON is minted on demand as a 1:1-backed claim on real, custodied Eli Lilly shares through a regulated broker-dealer structure, with published documentation and audits but notable centralization around trusted operational roles.
3. Financial Health (4 criteria)
| Criterion | Score | Analysis |
|---|
| Protocol Revenue | 72/100 | Platform revenue is fee-based (management/mint/redeem) rather than interest-based for the equity-tracker line, though not broken out per-asset. |
| Financial Status | 85/100 | Ondo Global Markets/Stocks is reported as the largest tokenized-stock platform with over $1B TVL and rapid, sustained growth. |
| Interest Assessment | 50/100 | The base protocol itself does not natively lend against LLYON today, but Ondo Global Markets has stated plans for native margin/Prime Brokerage borrowing, and third-party DeFi already permits interest-based borrowing against the token as collateral. |
| Audit Quality | 82/100 | Multiple named firms (CertiK, PeckShield, Halborn, EtherAuthority, Zellic) have audited the Ondo/Global Markets contracts across 2021-2025 with findings largely resolved. |
Summary: The platform is fee-revenue-based and financially strong with large and growing TVL, though the base platform has stated intentions to add native interest-based margin/borrowing and third-party DeFi already allows borrowing against the token, alongside multiple named third-party audits.
4. Token Economics (5 criteria)
| Criterion | Score | Analysis |
|---|
| Token Purpose | 90/100 | LLYON is designed as a genuine security-tracking utility instrument, not a meme token. |
| Governance Rights | N/A | LLYON holders are not described as having protocol governance rights, and this absence is consistent with it being a pure asset-tracker rather than a governance instrument, raising no independent Shariah concern. |
| Rewards Distribution | 85/100 | Rewards are variable, tied to actual dividend events of the underlying stock and reinvested into token value rather than paid as a fixed or interest-like rate. |
| Speculation Controls | 48/100 | The only described speculation-limiting feature is that minting/redemption is restricted to trading hours; no other anti-speculation mechanisms are documented. |
| Asset Backing | 90/100 | The token is explicitly stated to be fully backed 1:1 by real, custodied Eli Lilly shares. |
Summary: LLYON functions as a genuine utility/security-tracker token with dividend-linked variable rewards and full asset backing, though it carries no independent governance rights and only limited disclosed anti-speculation controls.
5. Staking Mechanism
Eli Lilly (Ondo Tokenized Stock) has no native staking mechanism, so these five criteria are not applicable and are excluded from the score entirely rather than counted as zeros.
Overall Assessment: LLYON presents as a credibly-run, asset-backed equity-tracking token with real utility and no evidence of fraud, but has centralization features, undisclosed underlying-company debt/interest screening data, and a stated move toward native interest-based margin financing that warrant continued monitoring.
Written by ThanvirFounder, Ex Director S&P Global Energy
Reviewed by Imam Omar SiddiqiShariah Scholar